Win the digital race in pharma

The Bristol-Myers Squibb-Pfizer Alliance Continues Strong Leadership for Nonvalvular AFib Patients

Atrial fibrillation (AFib) is a leading risk factor for stroke; however, it can often go undetected. In October, the BMS-Pfizer Alliance and Fitbitannounced we are working together to help address gaps in AFib detection and accelerate diagnosis. The Alliance also announced the start of the potentially practice-changing GUARD-AF study, a randomized,controlled trial  in a real-world setting, to see if AFib screening and earlier detection and diagnosis could impact the rate of stroke, as well as bleeding leading to hospitalization, compared to usual medical care. These opportunities break new ground, demonstrating our commitment to patients and to trusted leadership in this space for years to come.
Unleash the power of our people
Deliver first-in-class science
Transform our go-to-market model
Win the digital race in pharma
Lead the conversation